Increased Survival in Low Birth Weight Neonates Given Prophylactic Surfactant

Journal of Perinatology

Volumn 18, Issue 6 SUPPL. 1, 1998, Pages 431-435

  Brown, David R ^a   Bloom, Barry T ^b   Cohen, Morris ^a   Myers, Michael M ^a   Egan, Edmund A ^c   Kattwinkel, John ^c   Delmore, Paula ^b   Hall, Robert T ^c   Malloy, Michael H ^c   Holzman, Ian R ^c   Carlo, Waldemar A ^c   Pramanik, Arun K ^c   McCaffree, Mary Anne ^c   Weatherstone, Kathleen B ^c   Willett, Lynne D ^c   Topper, William H ^c  

^a NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

^b WESLEY MEDICAL CENTER   (United States)

^c Newark Beth Israel Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT;

ARTICLE; BRAIN HEMORRHAGE; HUMAN; HYALINE MEMBRANE DISEASE; INFANT MORTALITY; NEWBORN; RETROSPECTIVE STUDY; RISK FACTOR; VERY LOW BIRTH WEIGHT;

CEREBRAL HEMORRHAGE; HUMANS; HYALINE MEMBRANE DISEASE; INFANT MORTALITY; INFANT, NEWBORN; INFANT, VERY LOW BIRTH WEIGHT; PULMONARY SURFACTANTS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 0032196615     PISSN: 07438346     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Kwong MS, Egan EA, Notter RH, Shapiro DL. Double-blind trial of calf lung surfactant extract for the prevention of hyaline membrane disease in extremely premature infants. Pediatrics 1985;76:585-92.
2. Corbet A, Bucciarelli R, Goldman S, Mammel M, Wold D, Long W, and the American Exosurf Pediatric Study Group 1. Decreased mortality rate among small premature infants treated at birth with a single dose of synthetic surfactant: a multicenter controlled trial. J Pediatr 1991;118: 277-84.
3. Long W, Thompson T, Sundell H, Schumacher R, Volberg F, Guthrie R, and the American Exosurf Neonatal Study Group 1. Effects of two rescue doses of a synthetic surfactant on mortality rate and survival without bronchopulmonary dysplasia in 700- to 1350-gram infants with respiratory distress syndrome. J Pediatr 1991;118:595-605.
4. Hoekstra RE, Jackson C, Myers TF, et al. Improved neonatal survival following multiple doses of bovine surfactant in very premature neonates at risk for respiratory distress syndrome. Pediatrics 1991;88:10-8.
5. Liechty EA, Donovan E, Purohit D, et al. Reduction of neonatal mortality after multiple doses of bovine surfactant in low birth weight neonates with respiratory distress syndrome. Pediatrics 1991;88:19-28.
6. Speer CP, Robertson B, Curstedt T, et al. Randomized European multicenter trial of surfactant replacement therapy for severe neonatal respiratory distress syndrome: single versus multiple doses of Curosurf. Pediatrics 1992;89:13-20.
7. Nilsson R, Grossmann G, Robertson B. Lung surfactant and the pathogenesis of neonatal bronchiolar lesions induced by artificial ventilation. Pediatr Res 1978;12:249-55.
8. Jobe A, Ikegami M, Jacobs H. Permeability of premature lamb lungs to protein and the effect of surfactant on that permeability. J Appl Physiol 1983;55:169-76.
9. Maeta H, Vidyasagar D, Raju TNK, Bhat R, Matsuda H. Early and late surfactant treatments in baboon model of hyaline membrane disease. Pediatrics 1988;81:277-83.
10. Kobayashi T, Nitta K, Ganzuka M, et al. Inactivation of exogenous surfactant by pulmonary edema fluid. Pediatr Res 1991;29:353-6.
11. Kendig JW, Notter RH, Cox C, et al. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation. N Engl J Med 1991;324:865-71.
12. Dunn MS, Shennan AT, Zayack D, Possmayer F. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: a randomized controlled trial of prophylaxis versus treatment. Pediatrics 1991;87:377-86.
13. Merritt TA, Hallman M, Berry C, et al. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity. J Pediatr 1991;118:581-94.
14. The OSIRIS Collaborative Group. Early versus delayed neonatal administration of a synthetic surfactant - the judgment of OSIRIS. Lancet 1992;340:1363-9.
15. Kattwinkel J, Bloom BT, Delmore P, et al. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation. Pediatrics 1993;92:90-8.
16. Egberts J, de Winter JP, Sedin G, et al. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: a randomized trial. Pediatrics 1993;92:768-74.
17. Pramanik AK, Holtzman RB, Merritt AT. Surfactant replacement therapy for pulmonary diseases. Pediatr Clin North Am 1993;40:913-36.
18. Oh W, Fanaroff AA, Verter J, et al. Neonatal mortality and morbidities in very low birth weight (VLBW) infants: a seven-year trend analysis of the Neonatal Research Network data. Pediatr Res 1996;39:235A.
19. Bloom BT, Kattwinkel J, Hall RT, et al. Comparison of two bovine surfactants in the treatment and prevention of RDS. Pediatrics 1997;100: 31-8.
20. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-48.
21. Papageorgiou AN, Desgranges MF, Masson M, Colle E, Shatz R, Gelfand MM. The antenatal use of betamethasone in the prevention of respiratory distress syndrome: a controlled double-blind study. Pediatrics 1979;63:73-9.
22. Doran TA, Swyer P, MacMurray B, et al. Results of a double-blind controlled study on the use of betamethasone in the prevention of respiratory distress syndrome. Am J Obstet Gynecol 1980;136:313-20.
23. Smolders-de Haas H, Neuvel J, Schmand B, Treffers PE, Koppe JG, Hoeks J. Physical development and medical history of children who were treated antenatally with corticosteroids to prevent respiratory distress syndrome: a 10- to 12-year follow-up. Pediatrics 1990;85:65-70.
24. Ryan CA, Finer NN. Antenatal corticosteroid therapy to prevent respiratory distress syndrome. J Pediatr 1995;126:317-9.
25. Kari MA, Hallman M, Eronen M, et al. Prenatal dexamethasone treatment in conjunction with rescue therapy of human surfactant: a randomized placebo-controlled multi-center study. Pediatrics 1994;93:730-6.
26. Maniscalco WM, Kendig JW, Shapiro DL. Surfactant replacement therapy: impact on hospital charges for premature infants with respiratory distress syndrome. Pediatrics 1989;83:1-6.
27. Dunn MS. Surfactant replacement therapy: prophylaxis or treatment? Pediatrics 1993;92:148-50.
28. Brown DR, Barrett C, Cohen M, Myers MM. Strategy for prophylactic (PRO) surfactant (SURF) use based on standardized rates from patients (pts) treated with rescue (RESC) SURF in the multi-center Infasaurf-Survanta trial (IST): preliminary results from one center. Pediatr Res 1995;37:198A.
29. Merenstein GB, Cassady G, Erenberg A, et al. Surfactant replacement therapy for respiratory distress syndrome. Pediatrics 1991;87:946-7.
30. Avery ME, Merritt TA. Surfactant-replacement therapy. N Engl J Med 1991;324:910-2.
31. Whitsett JA, Hull WM, Luse S. Failure to detect surfactant protein-specific antibodies in sera of premature infants treated with Survanta, a modified bovine surfactant. Pediatrics 1991;87:505-10.
32. Chida S, Phelps DS, Soll RF, Taeusch HW. Surfactant proteins and anti-surfactant antibodies in sera from infants with respiratory distress syndrome with and without surfactant treatment. Pediatrics 1991;88:84-9.
33. Raju TNK, Langenberg P. Pulmonary hemorrhage and exogenous surfactant therapy: a meta-analysis. J Pediatr 1993;123:603-10.
34. Guyer B, Strobino DM, Ventura SJ, Singh GK. Annual summary of vital statistics - 1994. Pediatrics 1995; 96:1029-39.